CAR-T Cell Therapy for Lymphoma: How Does Radiation Therapy Fit In?

Publication date: Available online 28 September 2019Source: Practical Radiation OncologyAuthor(s): Alexandra D. Dreyfuss, Michael Lariviere, Leslie K. Ballas, John P. PlastarasAbstractCell-based immunotherapies have the potential to redefine modern oncologic care, providing promising new treatments for patients with otherwise poor prognoses. Chimeric antigen receptor (CAR) T cell therapy has produced remarkable remission rates in patients with even the most treatment-refractory hematologic malignancies. In 2018 the FDA approved two CAR-T cell therapies for relapsed/refractory aggressive non-Hodgkin lymphoma (r/rNHL). With the emergence of these novel therapies, there are many questions regarding treatment safety, tolerability, efficacy, and practicality with regards to radiotherapy. In this review we summarize the existing literature on CAR-T cell therapy in r/rNHL and propose a potential role for radiation therapy in the treatment of patients undergoing CAR-T cell therapy.
Source: Practical Radiation Oncology - Category: Cancer & Oncology Source Type: research